Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 6,471 shares of the company’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $57.08, for a total transaction of $369,364.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, June 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $51.46, for a total transaction of $257,300.00.
  • On Tuesday, May 14th, G Bradley Cole sold 11,424 shares of Genomic Health stock. The stock was sold at an average price of $57.17, for a total transaction of $653,110.08.

Shares of GHDX stock opened at $56.28 on Friday. The firm has a 50-day moving average price of $54.81. The stock has a market capitalization of $2.09 billion, a P/E ratio of 53.60 and a beta of 1.07. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.67 and a current ratio of 5.67. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.05. The company had revenue of $108.80 million during the quarter, compared to the consensus estimate of $106.75 million. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The firm’s revenue for the quarter was up 17.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.11) earnings per share. On average, equities research analysts predict that Genomic Health, Inc. will post 1.46 earnings per share for the current year.

Several research analysts have weighed in on GHDX shares. Deutsche Bank set a $18.00 price objective on shares of Commercial Metals and gave the stock a “buy” rating in a report on Thursday, May 30th. Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. ValuEngine downgraded shares of Valero Energy from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Piper Jaffray Companies reiterated a “buy” rating on shares of Beigene in a report on Thursday, June 20th. Finally, Needham & Company LLC set a $69.00 target price on shares of Genomic Health and gave the company a “buy” rating in a report on Wednesday, June 19th. Nine equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.86.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in Genomic Health by 7.6% during the fourth quarter. BlackRock Inc. now owns 2,191,689 shares of the medical research company’s stock valued at $141,167,000 after buying an additional 154,253 shares during the period. Acadian Asset Management LLC grew its position in Genomic Health by 20.5% during the first quarter. Acadian Asset Management LLC now owns 893,114 shares of the medical research company’s stock valued at $62,561,000 after buying an additional 151,846 shares during the period. FMR LLC grew its position in Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after buying an additional 251,085 shares during the period. OppenheimerFunds Inc. grew its position in Genomic Health by 30.0% during the first quarter. OppenheimerFunds Inc. now owns 469,560 shares of the medical research company’s stock valued at $32,893,000 after buying an additional 108,337 shares during the period. Finally, Clearbridge Investments LLC grew its position in Genomic Health by 21.6% during the first quarter. Clearbridge Investments LLC now owns 340,847 shares of the medical research company’s stock valued at $23,876,000 after buying an additional 60,432 shares during the period. Institutional investors own 95.54% of the company’s stock.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: Return On Assets

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.